Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2a,Condition 2b,Condition 3a,Condition 3b,Condition 4,Condition 5
753,"Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.",urine calcium amount,,RS:0000742,WKY,female,66 days to 60 days,3,,CMO:0000763,urine calcium excretion rate,,,,2.91,mg/d,0.1039,0.18,MMO:0000147,urine analysis,,86400.0,,,,,controlled calcium content diet (0.6 %) (between 4 and 10 days),67502,controlled calcium content diet (0.6 %) (between 4 and 10 days),,,,,,
753,"Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.",urine calcium amount,,RS:0000742,WKY,male,66 days to 60 days,3,,CMO:0000763,urine calcium excretion rate,,,,0.95,mg/d,0.0751,0.13,MMO:0000147,urine analysis,,86400.0,,,,,controlled calcium content diet (0.6 %) (between 4 and 10 days),67503,controlled calcium content diet (0.6 %) (between 4 and 10 days),,,,,,
206,"Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46",arterial blood pressure trait,,RS:0000742,WKY,male,175 days,24,,CMO:0000004,systolic blood pressure,,,continuous mean,167.3,mmHg,2.3678,11.6,MMO:0000011,vascular indwelling catheter method,aorta,,,,,,naive control condition,11901,naive control condition,,,,,,
206,"Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46",arterial blood pressure trait,,RS:0000742,WKY,male,175 days,24,,CMO:0000005,diastolic blood pressure,,,continuous mean,102.1,mmHg,2.4699,12.1,MMO:0000011,vascular indwelling catheter method,aorta,,,,,,naive control condition,11902,naive control condition,,,,,,
206,"Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46",arterial blood pressure trait,,RS:0000742,WKY,male,112 days,28,,CMO:0000009,mean arterial blood pressure,,,continuous mean,120.6,mmHg,1.3418,7.1,MMO:0000031,tail cuff plethysmography,,0,animals were prewarmed to 34 degrees C for 20 min before BP,,,,naive control condition,65080,naive control condition,,,,,,
206,"Frantz SA, et al., Hypertension 1998 Oct;32(4):639-46",arterial blood pressure trait,,RS:0000742,WKY,male,140 days,28,,CMO:0000009,mean arterial blood pressure,,,continuous mean,126,mmHg,1.3796,7.3,MMO:0000031,tail cuff plethysmography,,0,animals were prewarmed to 34 degrees C for 20 min before BP,,,,naive control condition,65084,naive control condition,,,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",arterial blood pressure trait,,RS:0000742,WKY,male,91 days,4,,CMO:0000004,systolic blood pressure,,average of 3 consistent readings,serial mean,131.7,mmHg,2.25,4.5,MMO:0000052,tail cuff photoplethysmography,,0,UR1000; Ueda,,,,controlled sodium content diet (0.4 %) (for 63 days),12584,controlled sodium content diet (0.4 %) (for 63 days),,,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",arterial blood pressure trait,,RS:0000742,WKY,female,91 days,4,,CMO:0000004,systolic blood pressure,,average of 3 consistent readings,serial mean,127,mmHg,5.75,11.5,MMO:0000052,tail cuff photoplethysmography,,0,UR1000; Ueda,,,,controlled sodium content diet (0.4 %) (for 63 days),12585,controlled sodium content diet (0.4 %) (for 63 days),,,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",body mass,,RS:0000742,WKY,male,360 days,4,,CMO:0000012,body weight,,,,318,g,6.65,13.3,MMO:0000016,body weighing method,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12588,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",body mass,,RS:0000742,WKY,female,360 days,4,,CMO:0000012,body weight,,,,200.8,g,3.45,6.9,MMO:0000016,body weighing method,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12589,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",heart mass,,RS:0000742,WKY,male,360 days,4,,CMO:0000069,heart wet weight,,,,0.784,g,0.031,0.062,MMO:0000005,post excision weight measurement,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12592,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",heart mass,,RS:0000742,WKY,male,360 days,4,,CMO:0000074,heart weight to body weight ratio,,,,2.5,g/kg,0.1,0.2,MMO:0000005,post excision weight measurement,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12593,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",heart mass,,RS:0000742,WKY,female,360 days,4,,CMO:0000069,heart wet weight,,,,0.554,g,0.02,0.04,MMO:0000005,post excision weight measurement,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12594,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",heart mass,,RS:0000742,WKY,female,360 days,4,,CMO:0000074,heart weight to body weight ratio,,,,2.8,g/kg,0.1,0.2,MMO:0000005,post excision weight measurement,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12596,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),,,,,
831,"Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12.",urine calcium amount,,RS:0000742,WKY,male,61 days,8,,CMO:0000763,urine calcium excretion rate,,,,0.78,mg/d,0.0672,0.19,MMO:0000173,spectrophotometry,,0.0,,,,,controlled calcium content diet (1.2 %) (between 5 and 9 days),67890,controlled calcium content diet (1.2 %) (between 5 and 9 days),,,,,,
831,"Hoopes RR Jr, et al., J Am Soc Nephrol. 2006 May;17(5):1292-304. Epub 2006 Apr 12.",urine calcium amount,,RS:0000742,WKY,female,61 days,8,,CMO:0000763,urine calcium excretion rate,,,,2.11,mg/d,0.1768,0.5,MMO:0000173,spectrophotometry,,0.0,,,,,controlled calcium content diet (1.2 %) (between 5 and 9 days),67892,controlled calcium content diet (1.2 %) (between 5 and 9 days),,,,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",drinking behavior trait,,RS:0000742,WKY,male,90 days to 80 days,5,,CMO:0001616,ethanol drink intake rate to body weight ratio,,,,0.56,g/d/kg,0.085,0.19,MMO:0000212,ex vivo volume measurement method,,0.0,,,,,controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days),69898,controlled ethanol content drinking water (10 %) (for 2 days),water (for 14 days),controlled ethanol content drinking water (10 %) (for 14 days),,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",drinking behavior trait,,RS:0000742,WKY,female,90 days to 80 days,11,,CMO:0001616,ethanol drink intake rate to body weight ratio,,,,2.54,g/d/kg,2.8644,9.5,MMO:0000212,ex vivo volume measurement method,,0.0,,,,,controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days),69899,controlled ethanol content drinking water (10 %) (for 2 days),water (for 14 days),controlled ethanol content drinking water (10 %) (for 14 days),,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",drinking behavior trait,,RS:0000742,WKY,male,90 days to 80 days,5,,CMO:0001591,ethanol intake volume to total fluid intake volume ratio,,,,10.2,%,1.6547,3.7,MMO:0000212,ex vivo volume measurement method,,0.0,,,,,controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days),69900,controlled ethanol content drinking water (10 %) (for 2 days),water (for 14 days),controlled ethanol content drinking water (10 %) (for 14 days),,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",drinking behavior trait,,RS:0000742,WKY,female,90 days to 80 days,11,,CMO:0001591,ethanol intake volume to total fluid intake volume ratio,,,,45.7,%,3.2865,10.9,MMO:0000212,ex vivo volume measurement method,,0.0,,,,,controlled ethanol content drinking water (10 %) (for 2 days) then water (for 14 days) and controlled ethanol content drinking water (10 %) (for 14 days),69901,controlled ethanol content drinking water (10 %) (for 2 days),water (for 14 days),controlled ethanol content drinking water (10 %) (for 14 days),,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",ethanol metabolism trait,,RS:0000742,WKY,male,90 days to 80 days,N/A,,CMO:0001773,decrease in blood ethanol level to body weight ratio per unit time,,,,315,mg/kg/h,,6.0,MMO:0000403,enzymatic microassay,,0.0,,,,,ethanol (20 %) (between 0.5 and 3.5 hours),96820,ethanol (20 %) (between 0.5 and 3.5 hours),,,,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",ethanol metabolism trait,,RS:0000742,WKY,female,90 days to 80 days,N/A,,CMO:0001773,decrease in blood ethanol level to body weight ratio per unit time,,,,379,mg/kg/h,,8.0,MMO:0000403,enzymatic microassay,,0.0,,,,,ethanol (20 %) (between 0.5 and 3.5 hours),97040,ethanol (20 %) (between 0.5 and 3.5 hours),,,,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",ethanol metabolism trait,,RS:0000742,WKY,male,90 days to 80 days,N/A,,CMO:0001772,blood ethanol clearance rate,,,,33.6,mg/dl/h,,1.1,MMO:0000403,enzymatic microassay,,0.0,,,,,ethanol (20 %) (between 0.5 and 3.5 hours),97043,ethanol (20 %) (between 0.5 and 3.5 hours),,,,,,
1238,"Terenina-Rigaldie E, et al., Pharmacogenetics 2003 Sep;13(9):543-54.",ethanol metabolism trait,,RS:0000742,WKY,female,90 days to 80 days,N/A,,CMO:0001772,blood ethanol clearance rate,,,,41.3,mg/dl/h,,3.1,MMO:0000403,enzymatic microassay,,0.0,,,,,ethanol (20 %) (between 0.5 and 3.5 hours),97044,ethanol (20 %) (between 0.5 and 3.5 hours),,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,17.1,ml/d,1.57,4.9648,MMO:0000357,urine volume measurement method,,0.0,,,,days,vehicle control condition (1 null) ,99119,vehicle control condition (1 null) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,140.19,ml/d,10.38,32.8244,MMO:0000357,urine volume measurement method,,0.0,,,,days,streptozotocin (60 mg/kg) ,99120,streptozotocin (60 mg/kg) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,133.86,ml/d,16.58,52.4306,MMO:0000357,urine volume measurement method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,99121,streptozotocin (60 mg/kg) ,gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,62.68,ml/d,15.67,49.5529,MMO:0000357,urine volume measurement method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,99122,streptozotocin (60 mg/kg) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,58.33,ml/d,8.45,26.7212,MMO:0000357,urine volume measurement method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) ,99123,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",urine output,,RS:0000742,WKY,male,156 days,10,,CMO:0000260,timed urine volume,,,,53.91,ml/d,7.67,24.2547,MMO:0000357,urine volume measurement method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,99124,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000623,single kidney wet weight as percentage of body weight,,,,0.341,%,0.034,0.1075,MMO:0000005,post excision weight measurement,,0.0,,,,days,vehicle control condition (1 null) ,99113,vehicle control condition (1 null) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,5.47,g/kg,0.46,1.4546,MMO:0000005,post excision weight measurement,,0.0,,,,days,streptozotocin (60 mg/kg) ,99114,streptozotocin (60 mg/kg) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,5.42,g/kg,0.51,1.6128,MMO:0000005,post excision weight measurement,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,99115,streptozotocin (60 mg/kg) ,gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,4.46,g/kg,0.42,1.3282,MMO:0000005,post excision weight measurement,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,99116,streptozotocin (60 mg/kg) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,4.73,g/kg,0.37,1.17,MMO:0000005,post excision weight measurement,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) ,99117,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",kidney mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000622,single kidney wet weight to body weight ratio,,,,4.72,g/kg,0.31,0.9803,MMO:0000005,post excision weight measurement,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,99118,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 PFU) ,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,450.39,g,9.36,29.5989,MMO:0000016,body weighing method,,0.0,,,,days,vehicle control condition (1 null) ,99107,vehicle control condition (1 null) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,259.65,g,18.96,59.9568,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) ,99108,streptozotocin (60 mg/kg) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,261.43,g,21.34,67.483,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) ,99109,streptozotocin (60 mg/kg) ,gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,295.56,g,21.89,69.2223,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99110,streptozotocin (60 mg/kg) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,287.24,g,20.18,63.8148,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) ,99111,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,286.6,g,21.95,69.412,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99112,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,160.56,mg/dl,8.64,27.3221,MMO:0000073,radioimmunoassay,,0.0,,,,days,vehicle control condition (1 null) ,99101,vehicle control condition (1 null) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,520.92,mg/dl,28.8,91.0736,MMO:0000073,radioimmunoassay,,0.0,,,,days,streptozotocin (60 mg/kg) ,99102,streptozotocin (60 mg/kg) ,,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,533.7,mg/dl,25.56,80.8278,MMO:0000073,radioimmunoassay,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,99103,streptozotocin (60 mg/kg) ,gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 PFU) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,523.26,mg/dl,27.18,85.9507,MMO:0000073,radioimmunoassay,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99104,streptozotocin (60 mg/kg) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,537.12,mg/dl,28.98,91.6428,MMO:0000073,radioimmunoassay,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) ,99105,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,,,,
2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",blood glucose amount,,RS:0000742,WKY,male,156 days,10,,CMO:0000046,blood glucose level,,,,534.6,mg/dl,22.5,71.1512,MMO:0000073,radioimmunoassay,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99106,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",kidney glomerulus integrity trait,,RS:0000742,WKY,male,280 days,9,,CMO:0001269,kidney sclerotic glomeruli count to total glomeruli count ratio,,,,4,%,1.3333,4.0,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,naive control condition (for 280 days),100256,naive control condition (for 280 days),,,,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",kidney glomerulus integrity trait,,RS:0000742,WKY,male,280 days,9,,CMO:0002784,kidney sclerotic glomerular volume to total kidney glomerular volume ratio,,,,0.3,%,0.1333,0.4,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,naive control condition (for 280 days),100260,naive control condition (for 280 days),,,,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,280 days,9,,CMO:0002247,kidney glomerulus volume,,,,0.7,x 10E6 um3,0.0233,0.07,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,naive control condition (for 280 days),100252,naive control condition (for 280 days),,,,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",blood creatinine amount,,RS:0000742,WKY,male,280 days,9,,CMO:0000057,serum creatinine level,,,,0.53,mg/dl,0.0333,0.1,MMO:0000271,serum creatinine analysis,,0.0,,,,,naive control condition (for 280 days),100246,naive control condition (for 280 days),,,,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",total urine protein amount,,RS:0000742,WKY,male,280 days,9,,CMO:0000759,urine protein excretion rate,,,,20,mg/d,1.3333,4.0,MMO:0000335,urine total protein analysis,,0.0,,,,,naive control condition (for 280 days),100239,naive control condition (for 280 days),,,,,,
2459,"Macconi D, et al., Am J Pathol. 2009 Mar;174(3):797-807. Epub 2009 Jan 22.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days,9,,CMO:0000004,systolic blood pressure,undefined,,,130,mmHg,2.3333,7.0,MMO:0000031,tail cuff plethysmography,,0.0,,,,,naive control condition (for 280 days),100232,naive control condition (for 280 days),,,,,,
2826,"Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.",heart left ventricle mass,,RS:0000742,WKY,male,84 days,5,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.29,mg/g,0.03,0.0671,MMO:0000005,post excision weight measurement,,0.0,,,,,naive control condition (for 0 hours),103482,naive control condition (for 0 hours),,,,,,
2826,"Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.",body mass,,RS:0000742,WKY,male,84 days,5,,CMO:0000012,body weight,,,,260,g,7.0,15.6525,MMO:0000016,body weighing method,,0.0,,,,,naive control condition (for 0 hours),103476,naive control condition (for 0 hours),,,,,,
2826,"Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.",arterial blood pressure trait,,RS:0000742,WKY,male,84 days,5,,CMO:0000004,systolic blood pressure,,,,125,mmHg,2.0,4.4721,MMO:0000031,tail cuff plethysmography,,0.0,,,,,naive control condition (for 0 hours),103470,naive control condition (for 0 hours),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood VLDL triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0002688,blood very low density lipoprotein triglyceride level,,,,0.96192,mg/dl,0.2004,0.5302,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,standard diet (for 20 days),98922,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood VLDL triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0002688,blood very low density lipoprotein triglyceride level,,,,1.76352,mg/dl,0.1603,0.4242,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98923,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000548,plasma triglyceride level,,,,0.48,mmol/l,0.02,0.0529,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,standard diet (for 20 days),98918,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000548,plasma triglyceride level,,,,0.67,mmol/l,0.04,0.1058,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98919,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood HDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000646,plasma high density lipoprotein cholesterol level,,,,28.5714,mg/dl,1.1583,3.0646,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,standard diet (for 20 days),98914,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood HDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000646,plasma high density lipoprotein cholesterol level,,,,21.6216,mg/dl,1.5444,4.0861,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98915,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood LDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000647,plasma low density lipoprotein cholesterol level,,,,10.0386,mg/dl,1.1583,3.0646,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,standard diet (for 20 days),98910,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood LDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000647,plasma low density lipoprotein cholesterol level,,,,7.722,mg/dl,0.7722,2.043,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98911,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood VLDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000649,plasma very low density lipoprotein cholesterol level,,,,2.7027,mg/dl,0.3861,1.0215,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,standard diet (for 20 days),98906,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood VLDL cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000649,plasma very low density lipoprotein cholesterol level,,,,8.1081,mg/dl,0.7722,2.043,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98907,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000585,plasma total cholesterol level,,,,61.3899,mg/dl,4.2471,11.2368,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,standard diet (for 20 days),98902,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000585,plasma total cholesterol level,,,,66.0231,mg/dl,3.861,10.2152,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98903,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",liver triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0001598,liver triglyceride level,,,,11.42478196,mg/g,1.0796,2.8565,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,standard diet (for 20 days),98898,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",liver triglyceride amount,,RS:0000742,WKY,male,0 days,7,,CMO:0001598,liver triglyceride level,,,,19.00885488,mg/g,1.9823,5.2447,MMO:0000391,enzymatic triglyceride assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98899,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",liver cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0001597,liver cholesterol level,,,,3.9167645,mg/g,0.2397,0.6342,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,standard diet (for 20 days),98894,standard diet (for 20 days),,,,,,
2178,"Orolin J, et al., Food Chem Toxicol. 2009 Oct;47(10):2624-30. doi: 10.1016/j.fct.2009.07.022. Epub 2009 Jul 25.",liver cholesterol amount,,RS:0000742,WKY,male,0 days,7,,CMO:0001597,liver cholesterol level,,,,5.8886795,mg/g,0.3441,0.9105,MMO:0000390,enzymatic cholesterol assay,,0.0,,,,,controlled cholesterol content diet (1 %) (for 20 days),98895,controlled cholesterol content diet (1 %) (for 20 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",heart mass,,RS:0000742,WKY,male,112 days,6,,CMO:0000074,heart weight to body weight ratio,,,,2.43,g/kg,0.083,0.2033,MMO:0000005,post excision weight measurement,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),101687,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",heart mass,,RS:0000742,WKY,male,112 days,7,,CMO:0000074,heart weight to body weight ratio,,,,2.47,g/kg,0.026,0.0688,MMO:0000005,post excision weight measurement,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),101688,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood aldosterone amount,,RS:0000742,WKY,male,112 days,5,,CMO:0000551,plasma aldosterone level,,,,470,pg/ml,8.0,17.8885,MMO:0000073,radioimmunoassay,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),101691,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood aldosterone amount,,RS:0000742,WKY,male,112 days,6,,CMO:0000551,plasma aldosterone level,,,,1130,pg/ml,240.0,587.8775,MMO:0000073,radioimmunoassay,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),101692,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood angiotensin II amount,,RS:0000742,WKY,male,112 days,6,,CMO:0000572,plasma angiotensin II level,,,,41.3,pg/ml,11.5,28.1691,MMO:0000098,immunoassay,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),101689,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood angiotensin II amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000572,plasma angiotensin II level,,,,73.8,pg/ml,12.7,33.601,MMO:0000098,immunoassay,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),101690,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",arterial blood pressure trait,,RS:0000742,WKY,male,112 days,5,,CMO:0000004,systolic blood pressure,undefined,,,104,mmHg,2.0,4.4721,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),101683,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",arterial blood pressure trait,,RS:0000742,WKY,male,112 days,6,,CMO:0000004,systolic blood pressure,undefined,,,125,mmHg,2.0,4.899,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),101684,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",arterial blood pressure trait,,RS:0000742,WKY,male,112 days,5,,CMO:0000009,mean arterial blood pressure,undefined,,,66,mmHg,2.0,4.4721,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),101685,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",arterial blood pressure trait,,RS:0000742,WKY,male,112 days,6,,CMO:0000009,mean arterial blood pressure,undefined,,,79,mmHg,2.0,4.899,MMO:0000031,tail cuff plethysmography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),101686,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood corticosterone amount,,RS:0000742,WKY,female,0 days,6,,CMO:0001173,plasma corticosterone level,,,,123,ng/ml,32.0,78.3837,MMO:0000073,radioimmunoassay,,0.0,,,,,controlled calorie content diet (100 % of calories) (for 14 days),99072,controlled calorie content diet (100 % of calories) (for 14 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood corticosterone amount,,RS:0000742,WKY,female,0 days,6,,CMO:0001173,plasma corticosterone level,,,,409,ng/ml,28.0,68.5857,MMO:0000073,radioimmunoassay,,0.0,,,,,controlled calorie content diet (30 % of calories) (for 14 days),99071,controlled calorie content diet (30 % of calories) (for 14 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,not specified,1 days,26,,CMO:0000012,body weight,,,,6.64,g,0.14,0.7139,MMO:0000016,body weighing method,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99073,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,not specified,1 days,36,,CMO:0000012,body weight,,,,4.91,g,0.15,0.9,MMO:0000016,body weighing method,,0.0,,,,,in utero condition (30 % of calories) (for 22 days),99074,in utero condition (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,male,112 days,17,,CMO:0000012,body weight,,,,454,g,8.0,32.9848,MMO:0000016,body weighing method,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99075,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,male,112 days,18,,CMO:0000012,body weight,,,,436,g,11.0,46.669,MMO:0000016,body weighing method,,0.0,,,,,in utero condition (30 % of calories) (for 22 days),99076,in utero condition (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",kidney renin amount,,RS:0000742,WKY,male,112 days,5,,CMO:0002166,kidney renin level,,,,136.5,ng/ml/h,14.1,31.5286,MMO:0000444,enzyme activity assay,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99099,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",kidney renin amount,,RS:0000742,WKY,male,112 days,6,,CMO:0002166,kidney renin level,,,,145.3,ng/ml/h,11.1,27.1893,MMO:0000444,enzyme activity assay,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99100,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood renin amount,,RS:0000742,WKY,male,112 days,5,,CMO:0000116,plasma renin activity level,,,,0.43,ng/ml/h,0.05,0.1118,MMO:0000444,enzyme activity assay,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99097,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood renin amount,,RS:0000742,WKY,male,112 days,6,,CMO:0000116,plasma renin activity level,,,,0.48,ng/ml/h,0.08,0.196,MMO:0000444,enzyme activity assay,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99098,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood sodium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000060,plasma sodium level,,,,139.41,mmol/l,4.17,11.0328,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99089,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood sodium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000060,plasma sodium level,,,,148.97,mmol/l,4.08,10.7947,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99090,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood potassium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000061,plasma potassium level,,,,10.28,mmol/l,0.41,1.0848,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99091,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",blood potassium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000061,plasma potassium level,,,,11.98,mmol/l,1.12,2.9632,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99092,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",urine sodium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000129,urine sodium level,,,,57.21,mmol/l,17.0,44.9778,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99093,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",urine sodium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000129,urine sodium level,,,,55.41,mmol/l,18.4,48.6818,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99094,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",urine potassium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000128,urine potassium level,,,,122.72,mmol/l,30.2,79.9017,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99095,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",urine potassium amount,,RS:0000742,WKY,male,112 days,7,,CMO:0000128,urine potassium level,,,,112.58,mmol/l,26.7,70.6416,MMO:0000231,inductively coupled plasma-atomic emission spectrometry,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99096,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002746,kidney angiotensin I converting enzyme activity level,,,,0.35,nmol/min/mg,0.06,0.1342,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99085,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002741,heart angiotensin I converting enzyme activity level,,,,0.08,nmol/min/mg,0.01,0.0245,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99086,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002751,lung angiotensin I converting enzyme activity level,,,,13.33,nmol/min/mg,0.29,0.7104,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99087,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002746,kidney angiotensin I converting enzyme activity level,,,,0.39,nmol/min/mg,0.08,0.196,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99088,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002750,lung angiotensin I converting enzyme 2 activity level,,,,0.07,nmol/min/mg,0.02,0.0447,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99078,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002745,kidney angiotensin I converting enzyme 2 activity level,,,,1.69,nmol/min/mg,0.28,0.6261,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99079,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002740,heart angiotensin I converting enzyme 2 activity level,,,,0.02,nmol/min/mg,0.01,0.0245,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99080,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002750,lung angiotensin I converting enzyme 2 activity level,,,,0.14,nmol/min/mg,0.02,0.049,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99081,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,6,,CMO:0002745,kidney angiotensin I converting enzyme 2 activity level,,,,1.56,nmol/min/mg,0.37,0.9063,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (30 % of calories) (for 22 days),99082,controlled in utero environment (30 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002741,heart angiotensin I converting enzyme activity level,,,,0.08,nmol/min/mg,0.01,0.0224,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99083,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002751,lung angiotensin I converting enzyme activity level,,,,9.05,nmol/min/mg,1.46,3.2647,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99084,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",angiotensin I-converting enzyme activity,,RS:0000742,WKY,male,112 days,5,,CMO:0002740,heart angiotensin I converting enzyme 2 activity level,,,,0.02,nmol/min/mg,0.01,0.0224,MMO:0000394,high-performance liquid chromatography,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99077,controlled in utero environment (100 % of calories) (for 22 days),,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood total protein amount,,RS:0000742,WKY,male,0 days,9,,CMO:0002975,afferent arteriolar plasma protein concentration,,ca,,5.4,g/dl,0.1,0.3,MMO:0000427,plasma total protein analysis,renal afferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100567,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood total protein amount,,RS:0000742,WKY,male,0 days,6,,CMO:0002975,afferent arteriolar plasma protein concentration,,rt,,4.7,g/dl,0.2,0.4899,MMO:0000427,plasma total protein analysis,renal afferent arteriole,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100568,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood total protein amount,,RS:0000742,WKY,male,0 days,8,,CMO:0002975,afferent arteriolar plasma protein concentration,,ca,,5.6,g/dl,0.1,0.2828,MMO:0000427,plasma total protein analysis,renal afferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100569,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood total protein amount,,RS:0000742,WKY,male,0 days,9,,CMO:0002975,afferent arteriolar plasma protein concentration,,ca,,5.6,g/dl,0.1,0.3,MMO:0000427,plasma total protein analysis,renal afferent arteriole,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100570,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood total protein amount,,RS:0000742,WKY,male,0 days,8,,CMO:0002975,afferent arteriolar plasma protein concentration,,ca,,5.5,g/dl,0.1,0.2828,MMO:0000427,plasma total protein analysis,renal afferent arteriole,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100571,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000761,urine potassium excretion rate,,,,0.5184,mEq/d,0.1008,0.3024,MMO:0000435,urine potassium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100508,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000761,urine potassium excretion rate,,,,0.2016,mEq/d,0.0288,0.0762,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100509,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,5,,CMO:0000761,urine potassium excretion rate,,,,0.288,mEq/d,0.0864,0.1932,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100510,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000761,urine potassium excretion rate,,,,0.8496,mEq/d,0.0432,0.1222,MMO:0000435,urine potassium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100511,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000761,urine potassium excretion rate,,,,0.504,mEq/d,0.0432,0.1296,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100512,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000761,urine potassium excretion rate,,,,0.4896,mEq/d,0.0432,0.1222,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100513,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000761,urine potassium excretion rate,,,,1.9296,mEq/d,0.2736,0.8208,MMO:0000435,urine potassium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100514,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000761,urine potassium excretion rate,,,,1.7136,mEq/d,0.3456,0.9775,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100515,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000761,urine potassium excretion rate,,,,2.16,mEq/d,0.2736,0.8208,MMO:0000435,urine potassium analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100516,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000760,urine sodium excretion rate,,,,0.5328,mEq/d,0.072,0.216,MMO:0000434,urine sodium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100499,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000760,urine sodium excretion rate,,,,0.0288,mEq/d,0.0058,0.0152,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100500,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,5,,CMO:0000760,urine sodium excretion rate,,,,0.0432,mEq/d,0.0144,0.0322,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100501,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000760,urine sodium excretion rate,,,,0.6336,mEq/d,0.0288,0.0815,MMO:0000434,urine sodium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100502,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000760,urine sodium excretion rate,,,,0.3312,mEq/d,0.0432,0.1296,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100503,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000760,urine sodium excretion rate,,,,0.3024,mEq/d,0.0432,0.1222,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100504,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000760,urine sodium excretion rate,,,,0.5904,mEq/d,0.1584,0.4752,MMO:0000434,urine sodium analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100505,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000760,urine sodium excretion rate,,,,0.7344,mEq/d,0.2016,0.5702,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100506,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",urine sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000760,urine sodium excretion rate,,,,0.6912,mEq/d,0.2448,0.7344,MMO:0000434,urine sodium analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/kg) (for 497 days) then puromycin aminonucleoside (50 mg/l) ,100507,controlled enalapril content drinking water (50 mg/kg) (for 497 days),puromycin aminonucleoside (50 mg/l) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000061,plasma potassium level,,,,4.6,mmol/l,0.2,0.6,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100490,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000061,plasma potassium level,,,,5.9,mmol/l,0.3,0.7937,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100491,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,5,,CMO:0000061,plasma potassium level,,,,5.8,mmol/l,0.4,0.8944,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100492,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000061,plasma potassium level,,,,4.3,mmol/l,0.1,0.2828,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100493,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000061,plasma potassium level,,,,4.4,mmol/l,0.1,0.3,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100494,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000061,plasma potassium level,,,,4.7,mmol/l,0.3,0.8485,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100495,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000061,plasma potassium level,,,,4.2,mmol/l,0.2,0.6,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100496,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000061,plasma potassium level,,,,5,mmol/l,0.4,1.1314,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100497,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood potassium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000061,plasma potassium level,,,,4.7,mmol/l,0.3,0.9,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100498,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000060,plasma sodium level,,,,152,mmol/l,2.0,6.0,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100481,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000060,plasma sodium level,,,,149,mmol/l,3.0,7.9373,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100482,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,5,,CMO:0000060,plasma sodium level,,,,138,mmol/l,2.0,4.4721,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100483,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000060,plasma sodium level,,,,150,mmol/l,2.0,5.6569,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100484,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000060,plasma sodium level,,,,148,mmol/l,1.0,3.0,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100485,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000060,plasma sodium level,,,,148,mmol/l,2.0,5.6569,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100486,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000060,plasma sodium level,,,,143,mmol/l,3.0,9.0,MMO:0000553,automated plasma analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100487,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000060,plasma sodium level,,,,142,mmol/l,5.0,14.1421,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100488,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood sodium amount,,RS:0000742,WKY,male,0 days,9,,CMO:0000060,plasma sodium level,,,,146,mmol/l,3.0,9.0,MMO:0000553,automated plasma analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100489,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0001914,renal plasma flow,,,,3.9,ml/min,0.2,0.4472,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100600,,puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0001914,renal plasma flow,,,,4.6,ml/min,0.1,0.2236,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) ,100601,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0001914,renal plasma flow,,,,4.36,ml/min,0.36,0.805,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100602,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0001914,renal plasma flow,,,,4.37,ml/min,0.24,0.5367,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours),100603,puromycin aminonucleoside (50 mg/kg) ,0.9% sodium chloride solution (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002968,afferent arteriolar plasma flow rate,,afferent arteriolar plasma flow rate,,165,nl/min,17.0,51.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100527,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002968,afferent arteriolar plasma flow rate,,afferent arteriolar plasma flow rate,,186,nl/min,17.0,41.6413,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100528,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002968,afferent arteriolar plasma flow rate,,afferent arteriolar plasma flow rate,,191,nl/min,16.0,45.2548,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100529,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002968,afferent arteriolar plasma flow rate,,afferent arteriolar plasma flow rate,,169,nl/min,14.0,42.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100530,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002968,afferent arteriolar plasma flow rate,,afferent arteriolar plasma flow rate,,244,nl/min,21.0,59.397,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100531,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0001914,renal plasma flow,,,,4.5,ml/min,0.21,0.63,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100463,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,7,,CMO:0001914,renal plasma flow,,,,3.66,ml/min,0.62,1.6404,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100464,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0001914,renal plasma flow,,,,3.95,ml/min,0.7,1.5652,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100465,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001914,renal plasma flow,,,,4.65,ml/min,0.55,1.5556,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100466,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0001914,renal plasma flow,,,,3.79,ml/min,0.19,0.57,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100467,,puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001914,renal plasma flow,,,,4.15,ml/min,0.32,0.9051,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100468,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0001914,renal plasma flow,,,,4.99,ml/min,0.5,1.5,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100469,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001914,renal plasma flow,,,,4.18,ml/min,0.47,1.3294,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100470,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,9,,CMO:0001914,renal plasma flow,,,,5.45,ml/min,0.19,0.57,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100471,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002968,afferent arteriolar plasma flow rate,,qa,,270,nl/min,44.0,98.387,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100612,,puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",renal blood flow trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002968,afferent arteriolar plasma flow rate,,qa,,314,nl/min,34.0,76.0263,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) (for 0.5 hours) then saralasin (0.3 mg/kg/hr) ,100613,puromycin aminonucleoside (50 mg/kg) (for 0.5 hours),saralasin (0.3 mg/kg/hr) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000490,blood glomerular filtration rate,,,,1.17,ml/min,0.05,0.15,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100454,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0000490,blood glomerular filtration rate,,,,0.31,ml/min,0.05,0.1323,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100455,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000490,blood glomerular filtration rate,,,,0.38,ml/min,0.08,0.1789,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100456,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000490,blood glomerular filtration rate,,,,1.34,ml/min,0.06,0.1697,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100457,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000490,blood glomerular filtration rate,,,,1.28,ml/min,0.06,0.18,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100458,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000490,blood glomerular filtration rate,,,,1.25,ml/min,0.09,0.2546,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100459,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000490,blood glomerular filtration rate,,,,1.51,ml/min,0.12,0.36,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100460,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000490,blood glomerular filtration rate,,,,1.14,ml/min,0.13,0.3677,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100461,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000490,blood glomerular filtration rate,,,,1.43,ml/min,0.09,0.27,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100462,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000490,blood glomerular filtration rate,,,,1.22,ml/min,0.03,0.0671,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100596,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000490,blood glomerular filtration rate,,,,1.49,ml/min,0.09,0.2012,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100597,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000490,blood glomerular filtration rate,,,,1.24,ml/min,0.07,0.1565,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100598,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000490,blood glomerular filtration rate,,,,1.19,ml/min,0.08,0.1789,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours),100599,puromycin aminonucleoside (50 mg/kg) ,0.9% sodium chloride solution (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100604,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100605,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.29,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100606,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.28,,0.03,0.09,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours),100607,puromycin aminonucleoside (50 mg/kg) ,0.9% sodium chloride solution (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,82,nl/min,10.0,22.3607,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100609,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,65,nl/min,9.0,20.1246,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100610,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.162,nl/(s x mmHg),0.045,0.1006,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100617,puromycin aminonucleoside (50 mg/kg) ,saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,44.4,nl/min,4.0,12.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100517,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,17,nl/min,2.0,4.899,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100518,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,52,nl/min,3.0,8.4853,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100519,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,50,nl/min,3.0,9.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100520,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002945,single nephron glomerular filtration rate,,,,61,nl/min,3.0,8.4853,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100521,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002946,single nephron filtration fraction,,snff,,0.26,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100522,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002946,single nephron filtration fraction,,snff,,0.09,,0.004,0.0098,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100523,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002946,single nephron filtration fraction,,snff,,0.28,,0.02,0.0566,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100524,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002946,single nephron filtration fraction,,snff,,0.31,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100525,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002946,single nephron filtration fraction,,,,0.26,,0.02,0.0566,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100526,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.26,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100472,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002943,renal filtration fraction,,,,0.09,,0.004,0.0106,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100473,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002943,renal filtration fraction,,,,0.09,,0.01,0.0224,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100474,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.26,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100475,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.34,,0.02,0.06,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100476,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.28,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100477,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.32,,0.03,0.09,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100478,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.27,,0.01,0.0283,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100479,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002943,renal filtration fraction,,,,0.28,,0.01,0.03,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100480,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,67,nl/min,13.0,29.0689,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100608,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002945,single nephron glomerular filtration rate,,sngfr,,57,nl/min,8.0,17.8885,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours),100611,puromycin aminonucleoside (50 mg/kg) ,0.9% sodium chloride solution (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.055,nl/(s x mmHg),0.017,0.038,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100616,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000004,systolic blood pressure,,,,106,mmHg,3.0,9.0,MMO:0000031,tail cuff plethysmography,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100445,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,7,,CMO:0000004,systolic blood pressure,,,,112,mmHg,5.0,13.2288,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100446,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000004,systolic blood pressure,,,,95,mmHg,9.0,20.1246,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100447,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000004,systolic blood pressure,,,,117,mmHg,2.0,5.6569,MMO:0000031,tail cuff plethysmography,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100448,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000004,systolic blood pressure,,,,121,mmHg,2.0,6.0,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100449,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000004,systolic blood pressure,,,,100,mmHg,1.0,2.8284,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100450,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000004,systolic blood pressure,,,,108,mmHg,3.0,9.0,MMO:0000031,tail cuff plethysmography,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100451,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,8,,CMO:0000004,systolic blood pressure,,,,113,mmHg,4.0,11.3137,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100452,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,9,,CMO:0000004,systolic blood pressure,,,,96,mmHg,2.0,6.0,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100453,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000004,systolic blood pressure,,,,118,mmHg,4.0,8.9443,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,70,days,puromycin aminonucleoside (50 mg/kg) (for 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100593,puromycin aminonucleoside (50 mg/kg) (for 70 days),saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000004,systolic blood pressure,,,,127,mmHg,5.0,11.1803,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100594,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000004,systolic blood pressure,,,,131,mmHg,4.0,8.9443,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,,,0.9% sodium chloride solution (50 mg/kg) (for 0.5 hours) then 0.9% sodium chloride solution,100595,,0.9% sodium chloride solution (50 mg/kg) (for 0.5 hours),,0.9% sodium chloride solution,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",arterial blood pressure trait,,RS:0000742,WKY,male,0 days,5,,CMO:0000004,systolic blood pressure,,,,119,mmHg,3.0,6.7082,MMO:0000031,tail cuff plethysmography,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100592,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,41,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100436,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,7,,CMO:0000037,hematocrit,,,,39,%,1.0,2.6458,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100437,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,5,,CMO:0000037,hematocrit,,,,35,%,1.0,2.2361,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100438,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,45,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100439,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,43,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100440,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,43,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100441,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,44,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100442,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,8,,CMO:0000037,hematocrit,,,,44,%,1.0,2.8284,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100443,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,9,,CMO:0000037,hematocrit,,,,42,%,1.0,3.0,MMO:0000214,hematocrit analysis,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100444,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000116,plasma renin activity level,,,,7.4,ng/ml/h,0.8,2.7713,MMO:0000073,radioimmunoassay,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100425,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000116,plasma renin activity level,,,,206.8,ng/ml/h,20.7,71.7069,MMO:0000073,radioimmunoassay,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100426,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000116,plasma renin activity level,,,,10.7,ng/ml/h,1.7,5.3759,MMO:0000073,radioimmunoassay,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100421,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000116,plasma renin activity level,,,,8.8,ng/ml/h,1.0,3.3166,MMO:0000073,radioimmunoassay,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100422,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000116,plasma renin activity level,,,,100.3,ng/ml/h,18.6,58.8184,MMO:0000073,radioimmunoassay,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100423,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood renin amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000116,plasma renin activity level,,,,11.9,ng/ml/h,1.0,3.3166,MMO:0000073,radioimmunoassay,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100424,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000550,serum albumin level,,,,3.5,g/dl,0.2,0.6325,MMO:0000439,radial immunodiffusion assay,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100415,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000550,serum albumin level,,,,1.3,g/dl,0.1,0.3317,MMO:0000439,radial immunodiffusion assay,,0.0,,PA IV 50mg/kg,23,days,puromycin aminonucleoside (50 mg/kg) ,100416,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000550,serum albumin level,,,,1.4,g/dl,0.1,0.3162,MMO:0000439,radial immunodiffusion assay,,0.0,,PA IV 50mg/kg,23,days,controlled enalapril content drinking water (50 mg/l) (for 30 days) then puromycin aminonucleoside (50 mg/kg) ,100417,controlled enalapril content drinking water (50 mg/l) (for 30 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000550,serum albumin level,,,,3.7,g/dl,0.2,0.6633,MMO:0000439,radial immunodiffusion assay,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100418,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000550,serum albumin level,,,,3.8,g/dl,0.1,0.3464,MMO:0000439,radial immunodiffusion assay,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100419,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood albumin amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000550,serum albumin level,,,,3.6,g/dl,0.1,0.3464,MMO:0000439,radial immunodiffusion assay,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100420,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000360,serum triglyceride level,,,,61,mg/dl,5.0,15.8114,MMO:0000136,serum triglyceride analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100409,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000360,serum triglyceride level,,,,231,mg/dl,25.0,82.9156,MMO:0000136,serum triglyceride analysis,,0.0,,PA IV 50mg/kg,19,days,puromycin aminonucleoside (50 mg/kg) ,100410,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000360,serum triglyceride level,,,,240,mg/dl,19.0,60.0833,MMO:0000136,serum triglyceride analysis,,0.0,,PA IV 50mg/kg,19,days,controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) ,100411,controlled enalapril content drinking water (50 mg/l) (for 26 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000360,serum triglyceride level,,,,55,mg/dl,6.0,19.8997,MMO:0000136,serum triglyceride analysis,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100412,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000360,serum triglyceride level,,,,73,mg/dl,5.0,17.3205,MMO:0000136,serum triglyceride analysis,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100413,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood triglyceride amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000360,serum triglyceride level,,,,72,mg/dl,9.0,31.1769,MMO:0000136,serum triglyceride analysis,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100414,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000363,serum total cholesterol level,,,,65,mg/dl,5.0,15.8114,MMO:0000132,serum total cholesterol measurement test,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100403,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000363,serum total cholesterol level,,,,240,mg/dl,15.0,49.7494,MMO:0000132,serum total cholesterol measurement test,,0.0,,PA IV 50mg/kg,19,days,puromycin aminonucleoside (50 mg/kg) ,100404,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000363,serum total cholesterol level,,,,360,mg/dl,45.0,142.3025,MMO:0000132,serum total cholesterol measurement test,,0.0,,PA IV 50mg/kg,19,days,controlled enalapril content drinking water (50 mg/l) (for 26 days) then puromycin aminonucleoside (50 mg/kg) ,100405,controlled enalapril content drinking water (50 mg/l) (for 26 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000363,serum total cholesterol level,,,,73,mg/dl,7.0,23.2164,MMO:0000132,serum total cholesterol measurement test,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100406,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000363,serum total cholesterol level,,,,88,mg/dl,5.0,17.3205,MMO:0000132,serum total cholesterol measurement test,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100407,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",blood cholesterol amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000363,serum total cholesterol level,,,,104,mg/dl,10.0,34.641,MMO:0000132,serum total cholesterol measurement test,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100408,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000759,urine protein excretion rate,,,,5,mg/d,1.0,3.1623,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100397,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000759,urine protein excretion rate,,,,112,mg/d,17.0,56.3826,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100398,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,10,,CMO:0000759,urine protein excretion rate,,,,115,mg/d,10.0,31.6228,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100399,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000759,urine protein excretion rate,,,,8,mg/d,1.0,3.3166,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100400,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000759,urine protein excretion rate,,,,13,mg/d,1.0,3.4641,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100401,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",total urine protein amount,,RS:0000742,WKY,male,0 days,12,,CMO:0000759,urine protein excretion rate,,,,10,mg/d,1.0,3.4641,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100402,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,249,g,11.0,36.4829,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100392,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,10,,CMO:0000012,body weight,,,,241,g,5.0,15.8114,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100393,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,244,g,8.0,24.0,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100427,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,7,,CMO:0000012,body weight,,,,245,g,9.0,23.8118,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100428,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,5,,CMO:0000012,body weight,,,,245,g,12.0,26.8328,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100429,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,317,g,10.0,28.2843,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100430,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,297,g,4.0,12.0,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100431,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,305,g,6.0,16.9706,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100432,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,412,g,6.0,18.0,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100433,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,418,g,15.0,42.4264,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100434,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,395,g,7.0,21.0,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100435,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,10,,CMO:0000012,body weight,,,,241,g,5.0,15.8114,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100391,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,319,g,5.0,16.5831,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100394,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,12,,CMO:0000012,body weight,,,,323,g,5.0,17.3205,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100395,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,12,,CMO:0000012,body weight,,,,312,g,4.0,13.8564,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100396,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,49,mmHg,1.0,3.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100532,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,50,mmHg,3.0,7.3485,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100533,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,47,mmHg,2.0,5.6569,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100534,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,68,mmHg,2.0,6.0,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100535,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,46,mmHg,2.0,5.6569,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100536,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002984,mean proximal tubular hydraulic pressure,,pt,,14,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100537,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002984,mean proximal tubular hydraulic pressure,,pt,,15,mmHg,1.0,2.4495,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100538,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002984,mean proximal tubular hydraulic pressure,,pt,,14,mmHg,1.0,2.8284,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100539,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002984,mean proximal tubular hydraulic pressure,,pt,,19,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100540,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002984,mean proximal tubular hydraulic pressure,,pt,,16,mmHg,1.0,2.8284,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100541,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002986,glomerular transcapillary hydraulic pressure gradient,,dp,,35,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100547,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002986,glomerular transcapillary hydraulic pressure gradient,,dp,,35,mmHg,3.0,7.3485,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100548,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002986,glomerular transcapillary hydraulic pressure gradient,,dp,,33,mmHg,2.0,5.6569,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100549,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002986,glomerular transcapillary hydraulic pressure gradient,,dp,,48,mmHg,2.0,6.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100550,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002986,glomerular transcapillary hydraulic pressure gradient,,dp,,31,mmHg,2.0,5.6569,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100551,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002977,afferent colloid osmotic pressure,,pia,,18.1,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal afferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100577,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002977,afferent colloid osmotic pressure,,pia,,12,mmHg,0.3,0.7348,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal afferent arteriole,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100578,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002977,afferent colloid osmotic pressure,,pia,,18,mmHg,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal afferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100579,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002977,afferent colloid osmotic pressure,,ce,,18,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal afferent arteriole,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100580,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002977,afferent colloid osmotic pressure,,pia,,18,mmHg,0.3,0.8485,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal afferent arteriole,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100581,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002978,efferent colloid osmotic pressure,,pie,,29,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100582,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002978,efferent colloid osmotic pressure,,pie,,14,mmHg,1.0,2.4495,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100583,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002978,efferent colloid osmotic pressure,,pie,,31,mmHg,1.0,2.8284,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100584,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002978,efferent colloid osmotic pressure,,pie,,33,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100585,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002978,efferent colloid osmotic pressure,,pie,,29,mmHg,2.0,5.6569,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,renal efferent arteriole,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100586,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.073,nl/(s x mmHg),0.012,0.036,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100587,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.015,nl/(s x mmHg),0.004,0.0098,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100588,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.092,nl/(s x mmHg),0.011,0.0311,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100589,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.039,nl/(s x mmHg),0.004,0.012,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100590,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002979,glomerular capillary ultrafiltration coefficient,,kf,,0.108,nl/(s x mmHg),0.026,0.0735,MMO:0000634,inulin analysis by liquid phase colorimetry,glomerular capillary,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,100591,controlled enalapril content drinking water (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,62,mmHg,2.0,4.4721,MMO:0000637,micropuncture fluid collection,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100614,,puromycin aminonucleoside (50 mg/kg) ,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,5,,CMO:0002969,glomerular capillary hydraulic pressure,,pgc,,51,mmHg,3.0,6.7082,MMO:0000637,micropuncture fluid collection,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) (between 56 and 70 days) then saralasin (0.3 mg/kg/hr) (for 0.5 hours),100615,puromycin aminonucleoside (50 mg/kg) (between 56 and 70 days),saralasin (0.3 mg/kg/hr) (for 0.5 hours),,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,22,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,109968,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,9,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,18,mmHg,1.0,3.0,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,109965,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,21,mmHg,1.0,2.4495,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,109966,puromycin aminonucleoside (50 mg/kg) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,17,mmHg,1.0,2.8284,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,109967,0.9% sodium chloride solution (3 ml) ,,,,,,
2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002985,efferent arteriolar hydraulic pressure,,pt,,24,mmHg,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,PA IV 50mg/kg,,,enalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) ,109969,enalapril (50 mg/l) (for 7 days),puromycin aminonucleoside (50 mg/kg) ,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000074,heart weight to body weight ratio,,,,3.5,g/kg,0.1,0.4123,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107451,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000074,heart weight to body weight ratio,,,,3.1,g/kg,0.1,0.4,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107453,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000074,heart weight to body weight ratio,,,,2.4,g/kg,0.1,0.3317,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107450,unilateral nephrectomy (for 150 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000074,heart weight to body weight ratio,,,,3.2,g/kg,0.1,0.4123,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107452,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",heart mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000074,heart weight to body weight ratio,,,,3.1,g/kg,0.1,0.4,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107454,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003489,kidney glomerular tuft surface area,,,,13.2,x 10E3 um2,3.3,13.6062,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107511,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003489,kidney glomerular tuft surface area,,kidney glomerulus surface area (CMO:0003488),,11.8,x 10E3 um2,2.9,11.957,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107512,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003489,kidney glomerular tuft surface area,,,,11.7,x 10E3 um2,2.9,11.6,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107514,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,16.4,x 10E3 um2,4.1,16.4,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107464,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,19.3,x 10E3 um2,4.8,19.7909,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107461,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003489,kidney glomerular tuft surface area,,,,8.7,x 10E3 um2,2.6,8.6232,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107510,unilateral nephrectomy (for 150 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003489,kidney glomerular tuft surface area,,kidney glomerulus surface area (CMO:0003488),,11.1,x 10E3 um2,2.8,11.2,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107513,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,11,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,12.6,x 10E3 um2,3.8,12.6032,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107460,unilateral nephrectomy (for 150 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,17,x 10E3 um2,4.1,16.9047,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107462,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney glomerulus morphology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0003488,kidney glomerular surface area,,kidney glomerulus surface area (CMO:0003488),,15.8,x 10E3 um2,4.0,16.0,MMO:0000561,ex vivo light microscopy with histochemistry,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107463,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,17,,CMO:0001954,left kidney wet weight to body weight ratio,,,,9.9,mg/g,0.7,2.8862,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107456,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,17,,CMO:0001954,left kidney wet weight to body weight ratio,,,,8.2,mg/g,0.2,0.8246,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107457,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,16,,CMO:0001954,left kidney wet weight to body weight ratio,,,,8.1,mg/g,0.2,0.8,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107458,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,16,,CMO:0001954,left kidney wet weight to body weight ratio,,,,8.3,mg/g,0.2,0.8,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107459,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney mass,,RS:0000742,WKY,male,0 days,11,,CMO:0001954,left kidney wet weight to body weight ratio,,,,3.9,mg/g,0.1,0.3317,MMO:0000005,post excision weight measurement,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107455,unilateral nephrectomy (for 150 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,11,,CMO:0001898,renal vascular resistance,,,,6.3,mmHg/ml/min,0.4,1.3266,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99995,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0001898,renal vascular resistance,,,,16.7,mmHg/ml/min,1.4,5.7723,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99996,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,17,,CMO:0001898,renal vascular resistance,,,,6.6,mmHg/ml/min,0.3,1.2369,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99997,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0001898,renal vascular resistance,,,,7.1,mmHg/ml/min,0.3,1.2,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99998,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,16,,CMO:0001898,renal vascular resistance,,,,6.8,mmHg/ml/min,0.3,1.2,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99999,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,7,,CMO:0001898,renal vascular resistance,,,,10,mmHg/ml/min,0.6,1.5875,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99960,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001898,renal vascular resistance,,,,9,mmHg/ml/min,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99961,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001898,renal vascular resistance,,,,8.8,mmHg/ml/min,0.5,1.4142,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99962,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,8,,CMO:0001898,renal vascular resistance,,,,9.2,mmHg/ml/min,0.4,1.1314,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99963,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney blood vessel physiology trait,,RS:0000742,WKY,male,0 days,6,,CMO:0001898,renal vascular resistance,,,,8.8,mmHg/ml/min,0.5,1.2247,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99964,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.28,ml/min/100g,0.07,0.2322,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99990,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002782,renal plasma flow to body weight ratio,,,,1.72,ml/min/100g,0.11,0.4535,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99991,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.3,ml/min/100g,0.11,0.4535,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99992,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.15,ml/min/100g,0.13,0.52,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99993,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.19,ml/min/100g,0.13,0.52,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99994,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.16,ml/min/100g,0.18,0.4762,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99950,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,3.09,ml/min/100g,0.18,0.5091,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99951,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.33,ml/min/100g,0.09,0.2546,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99952,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.32,ml/min/100g,0.11,0.3111,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99953,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",kidney plasma flow trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002782,renal plasma flow to body weight ratio,,,,2.42,ml/min/100g,0.09,0.2205,MMO:0000636,p-aminohippurate analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99954,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,11,,CMO:0000260,timed urine volume,,,,11.664,ml/d,1.008,3.3432,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,100000,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,17,,CMO:0000260,timed urine volume,,,,39.456,ml/d,4.608,18.9993,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,100001,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,17,,CMO:0000260,timed urine volume,,,,41.472,ml/d,4.464,18.4055,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),100002,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,16,,CMO:0000260,timed urine volume,,,,45.504,ml/d,5.04,20.16,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),100003,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,16,,CMO:0000260,timed urine volume,,,,49.248,ml/d,5.184,20.736,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),100004,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,7,,CMO:0000260,timed urine volume,,,,12.384,ml/d,2.016,5.3338,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99965,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,8,,CMO:0000260,timed urine volume,,,,23.472,ml/d,1.728,4.8875,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99966,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,8,,CMO:0000260,timed urine volume,,,,38.016,ml/d,5.328,15.0699,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99967,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,8,,CMO:0000260,timed urine volume,,,,41.616,ml/d,9.072,25.6595,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99968,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",urine output,,RS:0000742,WKY,male,0 days,6,,CMO:0000260,timed urine volume,,,,44.928,ml/d,8.784,21.5163,MMO:0000511,metabolic cage urine volume measurement method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99969,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,11,,CMO:0000046,blood glucose level,,,,76,mg/dl,1.0,3.3166,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99970,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,17,,CMO:0000046,blood glucose level,,,,324,mg/dl,13.0,53.6004,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99971,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,17,,CMO:0000046,blood glucose level,,,,312,mg/dl,24.0,98.9545,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99972,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,16,,CMO:0000046,blood glucose level,,,,308,mg/dl,15.0,60.0,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99973,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,16,,CMO:0000046,blood glucose level,,,,317,mg/dl,19.0,76.0,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99974,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,7,,CMO:0000046,blood glucose level,,,,74,mg/dl,2.0,5.2915,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99940,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000046,blood glucose level,,,,350,mg/dl,18.0,50.9117,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99941,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000046,blood glucose level,,,,352,mg/dl,17.0,48.0833,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99942,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,8,,CMO:0000046,blood glucose level,,,,357,mg/dl,11.0,31.1127,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99943,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",blood glucose amount,,RS:0000742,WKY,male,0 days,6,,CMO:0000046,blood glucose level,,,,367,mg/dl,12.0,29.3939,MMO:0000190,machine read blood glucose test strip,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99944,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,7,,CMO:0000012,body weight,,,,268,g,13.0,34.3948,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99935,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,215,g,10.0,28.2843,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99936,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,236,g,7.0,19.799,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99937,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,233,g,5.0,14.1421,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99938,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,6,,CMO:0000012,body weight,,,,229,g,6.0,14.6969,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99939,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000012,body weight,,,,256,g,5.0,20.6155,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107446,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000012,body weight,,,,274,g,6.0,24.7386,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107447,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,408,g,10.0,33.1662,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107445,unilateral nephrectomy (for 150 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000012,body weight,,,,267,g,9.0,36.0,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107449,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000012,body weight,,,,261,g,7.0,28.0,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107448,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 136 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.517,ml/min/100g,0.011,0.0365,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99980,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.496,ml/min/100g,0.029,0.1196,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99981,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.69,ml/min/100g,0.031,0.1278,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99982,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.664,ml/min/100g,0.022,0.088,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99983,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.673,ml/min/100g,0.021,0.084,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99984,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,11,,CMO:0002943,renal filtration fraction,,,,0.23,,0.01,0.0332,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99985,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002943,renal filtration fraction,,,,0.293,,0.011,0.0454,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99986,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,17,,CMO:0002943,renal filtration fraction,,,,0.214,,0.011,0.0454,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99987,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002943,renal filtration fraction,,,,0.216,,0.01,0.04,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99988,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,16,,CMO:0002943,renal filtration fraction,,,,0.213,,0.007,0.028,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99989,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.494,ml/min/100g,0.03,0.0794,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99945,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.792,ml/min/100g,0.03,0.0849,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99946,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.516,ml/min/100g,0.025,0.0707,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99947,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.536,ml/min/100g,0.017,0.0481,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99948,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002783,glomerular filtration rate to body weight ratio,,,,0.504,ml/min/100g,0.023,0.0563,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99949,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,7,,CMO:0002943,renal filtration fraction,,,,0.233,,0.013,0.0344,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99955,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.26,,0.013,0.0368,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99956,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.233,,0.12,0.3394,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99957,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,8,,CMO:0002943,renal filtration fraction,,,,0.234,,0.14,0.396,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99958,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",glomerular filtration trait,,RS:0000742,WKY,male,0 days,6,,CMO:0002943,renal filtration fraction,,,,0.21,,0.013,0.0318,MMO:0000634,inulin analysis by liquid phase colorimetry,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99959,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days),,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,11,,CMO:0000037,hematocrit,,,,45.2,%,1.4,4.6433,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99975,unilateral nephrectomy (for 28 days),vehicle control condition,,,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,44.8,%,0.6,2.4739,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99976,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,vehicle control condition,,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,17,,CMO:0000037,hematocrit,,,,45.6,%,0.3,1.2369,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days),99977,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,bosentan (100 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,45.8,%,0.5,2.0,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days),99978,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),,,
2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",erythrocyte quantity,,RS:0000742,WKY,male,0 days,16,,CMO:0000037,hematocrit,,,,44.5,%,0.6,2.4,MMO:0000214,hematocrit analysis,,0.0,,unx,168,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days),99979,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,,enalapril (10 mg/kg/d) (for 154 days),bosentan (100 mg/kg/d) (for 154 days),,
2338,"Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.",blood urea nitrogen amount,,RS:0000742,WKY,male,245 days,7,,CMO:0000049,blood urea nitrogen level,,,,19.5,mg/dl,0.9827,2.6,MMO:0000253,blood urea nitrogen analysis,,0.0,,,,,naive control condition,99857,naive control condition,,,,,,
2338,"Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.",heart mass,,RS:0000742,WKY,male,245 days,7,,CMO:0000074,heart weight to body weight ratio,,,,3.7,g/kg,0.0378,0.1,MMO:0000005,post excision weight measurement,,0.0,,,,,naive control condition,99853,naive control condition,,,,,,
2338,"Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.",body mass,,RS:0000742,WKY,male,245 days,7,,CMO:0000012,body weight,,,,373.6,g,11.1122,29.4,MMO:0000016,body weighing method,,0.0,,,,,naive control condition,99849,naive control condition,,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle wall thickness,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000987,heart ventricle septal wall thickness,,,,0.14,cm,0.01,0.0346,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100336,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle wall thickness,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000987,heart ventricle septal wall thickness,,,,0.13,cm,0.03,0.1342,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100337,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle wall thickness,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000987,heart ventricle septal wall thickness,,,,0.1,cm,0.004,0.0219,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100338,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle posterior wall thickness,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000238,heart posterior wall thickness,,,,0.17,cm,0.01,0.0346,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100345,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle posterior wall thickness,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000238,heart posterior wall thickness,,,,0.17,cm,0.01,0.0447,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100346,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle posterior wall thickness,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000238,heart posterior wall thickness,,,,0.18,cm,0.004,0.0219,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100347,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000985,heart left ventricle fractional shortening,,,,51.5,%,1.7,3.8013,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100303,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000985,heart left ventricle fractional shortening,,,,16.8,%,1.6,6.4,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100304,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000985,heart left ventricle fractional shortening,,,,18,%,1.5,8.4853,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100305,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,7.9,mm,0.2,0.4472,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100306,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,10.8,mm,0.3,1.2,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100307,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,10.6,mm,0.3,1.6971,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100308,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000983,heart left ventricle end-systolic diameter,,,,3.8,mm,0.3,0.6708,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100309,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000983,heart left ventricle end-systolic diameter,,,,9.1,mm,0.4,1.6,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100310,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000983,heart left ventricle end-systolic diameter,,,,8.8,mm,0.3,1.6971,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100311,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,8.3,mm,0.2,0.6928,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100339,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,10.6,mm,0.2,0.8944,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100340,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000982,heart left ventricular end-diastolic diameter,,,,10.6,mm,0.1,0.5477,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100341,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000983,heart left ventricle end-systolic diameter,,,,4.9,mm,0.3,1.0392,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100342,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000983,heart left ventricle end-systolic diameter,,,,9,mm,0.2,0.8944,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100343,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000983,heart left ventricle end-systolic diameter,,,,8.9,mm,0.2,1.0954,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100344,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000985,heart left ventricle fractional shortening,,,,41.1,%,3.0,10.3923,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100348,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000985,heart left ventricle fractional shortening,,,,15.1,%,1.0,4.4721,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100349,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle diameter,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000985,heart left ventricle fractional shortening,,,,15.8,%,0.7,3.8341,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100350,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000605,left ventricular end-systolic blood pressure,10 min mean,,continuous mean,93,mmHg,5.8,12.9692,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100321,sham surgical control condition (for 224 days),ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000605,left ventricular end-systolic blood pressure,10 min mean,,continuous mean,73.5,mmHg,4.7,18.8,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100322,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000605,left ventricular end-systolic blood pressure,10 min mean,,continuous mean,67.5,mmHg,3.9,22.0617,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100323,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,ketamine (80 mg/kg) ,xylazine (10 mg/kg)
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000606,left ventricular end-diastolic blood pressure,10 min mean,,continuous mean,5.5,mmHg,2.4,5.3666,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100324,sham surgical control condition (for 224 days),ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000606,left ventricular end-diastolic blood pressure,10 min mean,,continuous mean,9.36,mmHg,1.62,6.48,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100325,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000606,left ventricular end-diastolic blood pressure,10 min mean,,continuous mean,5.96,mmHg,0.84,4.7518,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100326,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,ketamine (80 mg/kg) ,xylazine (10 mg/kg)
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0001745,maximum rate of positive change in left ventricular blood pressure,10 min mean,,continuous mean,4225,mmHg/s,525.0,1173.9357,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100327,sham surgical control condition (for 224 days),ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0001745,maximum rate of positive change in left ventricular blood pressure,10 min mean,,continuous mean,2912,mmHg/s,300.0,1200.0,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100328,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricular blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0001745,maximum rate of positive change in left ventricular blood pressure,10 min mean,,continuous mean,2882,mmHg/s,208.0,1176.6257,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100329,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,ketamine (80 mg/kg) ,xylazine (10 mg/kg)
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",artery morphology trait,,RS:0000742,WKY,male,252 days to 238 days,11,,CMO:0002790,artery tunica media width to artery inner diameter ratio,,,,1.89,,0.12,0.398,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100386,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",artery morphology trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0002790,artery tunica media width to artery inner diameter ratio,,,,1.56,,0.1,0.3873,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100387,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",artery morphology trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0002790,artery tunica media width to artery inner diameter ratio,,,,1.82,,0.15,0.5809,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100388,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney glomerulus integrity trait,,RS:0000742,WKY,male,252 days to 238 days,11,,CMO:0001135,index of glomerular damage,,,,1.39,,0.03,0.0995,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100366,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney glomerulus integrity trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0001135,index of glomerular damage,,,,1.75,,0.03,0.1162,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100367,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney glomerulus integrity trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0001135,index of glomerular damage,,,,1.6,,0.03,0.1162,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100368,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney integrity trait,,RS:0000742,WKY,male,252 days to 238 days,11,,CMO:0001258,kidney fibrotic lesion area to total kidney area ratio,,,,0.91,%,0.03,0.0995,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100383,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney integrity trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0001258,kidney fibrotic lesion area to total kidney area ratio,,,,0.48,%,0.11,0.426,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100384,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney integrity trait,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0001258,kidney fibrotic lesion area to total kidney area ratio,,,,0.75,%,0.13,0.5035,MMO:0000560,ex vivo light microscopy with histochemistry and digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100385,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.41,mg/dl,0.03,0.0735,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100377,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.47,mg/dl,0.03,0.0735,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100378,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.52,mg/dl,0.04,0.098,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100379,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.41,mg/dl,0.03,0.0735,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100363,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.47,mg/dl,0.03,0.0735,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100364,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood creatinine amount,,RS:0000742,WKY,male,252 days to 238 days,6,,CMO:0000537,plasma creatinine level,,,,0.52,mg/dl,0.04,0.098,MMO:0000306,plasma creatinine analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100365,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,13.9,ml/d,1.6,4.2332,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100374,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,11.4,ml/d,2.4,6.3498,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100375,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,10.6,ml/d,2.2,5.8207,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100376,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,13.9,ml/d,1.6,4.2332,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100360,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,11.4,ml/d,2.4,6.3498,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100361,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",urine output,,RS:0000742,WKY,male,252 days to 238 days,7,,CMO:0000260,timed urine volume,,,,10.6,ml/d,2.2,5.8207,MMO:0000357,urine volume measurement method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100362,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000082,right kidney wet weight,,,,1.378,g,0.0706,0.2446,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100371,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3715,g,0.0374,0.1448,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100372,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3533,g,0.0439,0.17,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100373,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000082,right kidney wet weight,,,,1.378,g,0.0706,0.2446,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100357,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3715,g,0.0374,0.1448,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100358,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",kidney mass,,RS:0000742,WKY,male,252 days to 238 days,15,,CMO:0000082,right kidney wet weight,,,,1.3533,g,0.0439,0.17,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100359,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood potassium amount,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000495,serum potassium level,,,,5.3,mmol/l,0.37,0.8273,MMO:0000141,automated serum potassium test,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100333,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood potassium amount,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000495,serum potassium level,,,,5,mmol/l,0.19,0.76,MMO:0000141,automated serum potassium test,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100334,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood potassium amount,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000495,serum potassium level,,,,4.9,mmol/l,0.1,0.5657,MMO:0000141,automated serum potassium test,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100335,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood sodium amount,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000500,serum sodium level,,,,157.7,mmol/l,6.4,14.3108,MMO:0000142,automated serum sodium test,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100330,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood sodium amount,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000500,serum sodium level,,,,153.5,mmol/l,2.1,8.4,MMO:0000142,automated serum sodium test,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100331,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",blood sodium amount,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000500,serum sodium level,,,,155.1,mmol/l,1.1,6.2225,MMO:0000142,automated serum sodium test,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100332,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000004,systolic blood pressure,10 min mean,,continuous mean,97.8,mmHg,6.3,14.0872,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100315,sham surgical control condition (for 224 days),ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000004,systolic blood pressure,10 min mean,,continuous mean,79.5,mmHg,5.1,20.4,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100316,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000004,systolic blood pressure,10 min mean,,continuous mean,75.1,mmHg,2.4,13.5765,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100317,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,ketamine (80 mg/kg) ,xylazine (10 mg/kg)
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000005,diastolic blood pressure,10 min mean,,continuous mean,63.3,mmHg,6.9,15.4289,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100318,sham surgical control condition (for 224 days),ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000005,diastolic blood pressure,10 min mean,,continuous mean,53,mmHg,5.2,20.8,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100319,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ketamine (80 mg/kg) ,,xylazine (10 mg/kg) ,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",arterial blood pressure trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000005,diastolic blood pressure,10 min mean,,continuous mean,47.6,mmHg,2.7,15.2735,MMO:0000014,vascular transducer tipped catheter,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days) then ketamine (80 mg/kg) then xylazine (10 mg/kg) ,100320,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,ketamine (80 mg/kg) ,xylazine (10 mg/kg)
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000002,heart rate,,,,398,beats/min,37.0,82.7345,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100312,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000002,heart rate,,,,362,beats/min,31.0,124.0,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100313,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000002,heart rate,,,,373,beats/min,15.0,84.8528,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100314,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000180,ejection fraction,,,,75.8,%,3.9,13.51,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100351,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000180,ejection fraction,,,,35.5,%,2.0,8.9443,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100352,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000180,ejection fraction,,,,37,%,1.4,7.6681,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100353,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0002789,E/A wave ratio,,e/a wave,,1.39,,0.15,0.5196,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100354,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0002789,E/A wave ratio,,,,1.61,,0.21,0.9391,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100355,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0002789,E/A wave ratio,,,,1.85,,0.14,0.7668,MMO:0000337,echocardiography,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100356,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000180,ejection fraction,,,,86.8,%,1.5,3.3541,MMO:0000337,echocardiography,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100300,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000180,ejection fraction,,,,38.5,%,3.2,12.8,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100301,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart pumping trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000180,ejection fraction,,,,40.5,%,2.4,13.5765,MMO:0000337,echocardiography,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100302,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",lung mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000097,lung wet weight,,,,1.779,g,0.047,0.1628,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100297,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",lung mass,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000097,lung wet weight,,,,2.238,g,0.189,0.8452,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100298,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",lung mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000097,lung wet weight,,,,2.134,g,0.13,0.712,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100299,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000776,heart left ventricle weight,,,,0.847,g,0.027,0.0935,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100288,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000776,heart left ventricle weight,,,,0.963,g,0.119,0.5322,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100289,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000776,heart left ventricle weight,,,,0.969,g,0.079,0.4327,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100290,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000776,heart left ventricle weight,,,,0.84,g,0.022,0.0492,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100291,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000776,heart left ventricle weight,,,,1.037,g,0.127,0.508,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100292,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000776,heart left ventricle weight,,,,0.925,g,0.095,0.5374,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100293,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0002787,heart left ventricle weight to tibia length ratio,,lv/tl,,0.194,g/cm,0.005,0.0112,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100294,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0002787,heart left ventricle weight to tibia length ratio,,lv/tl,,0.24,g/cm,0.029,0.116,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100295,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0002787,heart left ventricle weight to tibia length ratio,,,,0.214,g/cm,0.02,0.1131,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100296,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000017,heart weight,,,,1.187,g,0.037,0.1282,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100276,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000017,heart weight,,,,1.563,g,0.417,1.8649,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100277,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000017,heart weight,,,,1.573,g,0.28,1.5336,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100278,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000017,heart weight,,,,1.266,g,0.07,0.1565,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100279,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000017,heart weight,,,,1.876,g,0.606,2.424,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100280,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000017,heart weight,,,,1.437,g,0.369,2.0874,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100281,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0001198,heart weight to tibia length ratio,,,,0.278,g/cm,0.007,0.0157,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100282,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0001198,heart weight to tibia length ratio,,,,0.396,g/cm,0.099,0.396,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100283,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0001198,heart weight to tibia length ratio,,,,0.314,g/cm,0.041,0.2319,MMO:0000005,post excision weight measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100284,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,12,,CMO:0000012,body weight,,,,223,g,1.4,4.8497,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,sham surgical control condition,100267,sham surgical control condition,,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,20,,CMO:0000012,body weight,,,,225,g,3.0,13.4164,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,left anterior descending coronary artery occlusion then furosemide,100268,left anterior descending coronary artery occlusion,furosemide,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,30,,CMO:0000012,body weight,,,,225,g,1.8,9.859,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,left anterior descending coronary artery occlusion then vehicle control condition,100269,left anterior descending coronary artery occlusion,vehicle control condition,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000012,body weight,,,,566,g,17.0,58.8897,MMO:0000016,body weighing method,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100270,sham surgical control condition (for 196 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000012,body weight,,,,583,g,56.0,250.4396,MMO:0000016,body weighing method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100271,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000012,body weight,,,,617,g,52.0,284.8157,MMO:0000016,body weighing method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100272,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000012,body weight,,,,562,g,22.0,49.1935,MMO:0000016,body weighing method,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100273,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000012,body weight,,,,599,g,35.0,140.0,MMO:0000016,body weighing method,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100274,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000012,body weight,,,,574,g,38.0,214.9605,MMO:0000016,body weighing method,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100275,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle integrity trait,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000687,heart left ventricle infarction size to total heart left ventricle size ratio,,,,35.2,%,4.5,20.1246,MMO:0000219,ex vivo microscopy with digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100263,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle integrity trait,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000687,heart left ventricle infarction size to total heart left ventricle size ratio,,,,35.8,%,5.4,29.577,MMO:0000219,ex vivo microscopy with digital image analysis,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100264,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle integrity trait,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000687,heart left ventricle infarction size to total heart left ventricle size ratio,,,,31.8,%,10.1,40.4,MMO:0000219,ex vivo microscopy with digital image analysis,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100265,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",heart left ventricle integrity trait,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000687,heart left ventricle infarction size to total heart left ventricle size ratio,,,,30.9,%,8.1,45.8205,MMO:0000219,ex vivo microscopy with digital image analysis,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100266,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",tibia length,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000450,tibia length,,,,4.3,cm,0.12,0.2683,MMO:0000276,post excision length measurement,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100285,sham surgical control condition (for 224 days),,,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",tibia length,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000450,tibia length,,,,4.3,cm,0.09,0.36,MMO:0000276,post excision length measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100286,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,,,,
2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",tibia length,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000450,tibia length,,,,4.3,cm,0.09,0.5091,MMO:0000276,post excision length measurement,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100287,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),,ramipril (1 mg/kg/d) (for 182 days),,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,125.3,mmHg,0.6803,1.8,MMO:0000031,tail cuff plethysmography,,,,,,,control condition,108357,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,123.7,mmHg,1.0583,2.8,MMO:0000031,tail cuff plethysmography,,,IP,XCO:0000750,60,min,diclofenac (10 mg/kg) (for 1 hours),108359,diclofenac (10 mg/kg) (for 1 hours),,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,122.8,mmHg,0.6047,1.6,MMO:0000031,tail cuff plethysmography,,,,,,,control condition,108361,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,122.6,mmHg,0.7446,1.97,MMO:0000031,tail cuff plethysmography,,,0.1% methylcellulose per os,XCO:0000750,60,min,diclofenac (20 mg/kg) (for 1 hours),108363,diclofenac (20 mg/kg) (for 1 hours),,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,123.4,mmHg,0.7559,2.0,MMO:0000031,tail cuff plethysmography,,,,,,,control condition,108365,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",blood pressure trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0000004,systolic blood pressure,,,,122.9,mmHg,0.7937,2.1,MMO:0000031,tail cuff plethysmography,,,0.1% methylcellulose per os,XCO:0000750,60,min,diclofenac (40 mg/kg) (for 1 hours),108367,diclofenac (40 mg/kg) (for 1 hours),,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,11.3,gx10,0.4082,1.08,MMO:0000733,Randall-Selitto test,,,,,,,control condition,108345,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,11.8,gx10,0.4498,1.19,MMO:0000733,Randall-Selitto test,,,0.1% methylcellulose per os,XCO:0000750,60,min,diclofenac (10 mg/kg) (for 1 hours),108347,diclofenac (10 mg/kg) (for 1 hours),,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,10.9,gx10,0.4271,1.13,MMO:0000733,Randall-Selitto test,,,,,,,control condition,108349,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,11.4,gx10,0.3364,0.89,MMO:0000733,Randall-Selitto test,,,0.1% methylcellulose per os,XCO:0000750,60,min,diclofenac (20 mg/kg) (for 1 hours),108351,diclofenac (20 mg/kg) (for 1 hours),,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,11,gx10,0.4536,1.2,MMO:0000733,Randall-Selitto test,,,,,,,control condition,108353,control condition,,,,,,
3101,"Romanowska K, et al., Acta Pol Pharm. 2008 Nov-Dec;65(6):723-9.",involuntary movement trait,,RS:0000742,WKY,male,120 days to 90 days,7,,CMO:0003567,measurement of minimal mechanical stimulus needed to elicit evasive reaction,,,,12.8,gx10,0.4006,1.06,MMO:0000733,Randall-Selitto test,,,0.1% methylcellulose per os,XCO:0000750,60,min,diclofenac (40 mg/kg) (for 1 hours),108355,diclofenac (40 mg/kg) (for 1 hours),,,,,,